Grifols, a CataloniaBio & HealthTech member, has entered into a formal collaboration with the Food and Drug Administration (FDA) and other public health agencies of United States to collect plasma from convalescent Covid-19 patients and process it into a hyperimmune globulin.

The agreement also includes to support preclinical and clinical studies to determine the efficacy of the new therapy as a viable treatment for Covid-19 disease and as a platform for future emerging infectious diseases.

In addition, Grifols has accelerated the development and validation of a proprietary technology TMA (transcription-mediated amplification) based diagnostic procedure with a hight sensitivity. The test will be performed on automatic instrumentation, with each unit able to run more than 1,000 samples per day, and that will be ready in the following weeks.

More information

Subscribirse al Directorio
Escribir un Artículo

Últimas Noticias

Tuneable reverse photochromes in the sol...

A new technique allows the design of solid materia...

La Unidad de Chequeos de la Clínica sup...

El estudio realizado sobre una muestra significati...

Destacadas

Entrevista con Dámaso Molero, director ...

by 3P Biopharmaceuticals

Dámaso Molero:" Creo que en Latinoamérica habrá negocio en el d...

Fully automated solution for SARS-CoV-2 ...

by Flomics Biotech SL

Our world is dealing with a global pandemic that threatens life as we ...

Diapositiva de Fotos